Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imagion Biosystems Ltd. ( (AU:IBX) ) just unveiled an announcement.
Imagion Biosystems Ltd. announced the completion of key milestones in its collaboration with Wayne State University, leading to the finalization of the Phase 2 study protocol for its MagSense® HER2 Breast Cancer clinical trial. The company plans to submit an Investigational New Drug application to the FDA in December 2025, with the trial expected to commence in early 2026. The collaboration has resulted in a reduced dose of the imaging agent, optimized MRI sequences, and the potential for AI-ready imaging data, enhancing patient safety and trial efficiency while reducing costs and improving clinical workflow.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
More about Imagion Biosystems Ltd.
Imagion Biosystems Ltd. is a company focused on improving healthcare outcomes through the early detection of cancer using its proprietary MagSense® imaging technology. The company targets various life-threatening cancer indications and is committed to delivering innovative solutions that can make a real difference for patients and their families.
Average Trading Volume: 9,178,999
Technical Sentiment Signal: Sell
Current Market Cap: A$10.77M
See more insights into IBX stock on TipRanks’ Stock Analysis page.